Previous studies demonstrated similar short-term effects of losartan and ramipril in STEMI patients on markers of heart failure such as NT-proBNP and ejection fraction (EF), as well as on markers of endogenous fibrinolysis such as PAI-1 [4]. The gene discussed is NPPB; the disease is heart failure.